NasdaqGS:LIVNMedical Equipment
LivaNova’s Aura6000 FDA Win Reshapes Obstructive Sleep Apnea Opportunity
FDA grants premarket approval to LivaNova's aura6000 System for adult patients with moderate to severe Obstructive Sleep Apnea who do not benefit from standard therapies.
The system uses proximal hypoglossal nerve stimulation and is supported by clinical trial data showing meaningful outcomes, including in harder to treat patient groups.
LivaNova (NasdaqGS:LIVN) also discloses work on a next generation, MRI compatible version of the aura6000 with additional features.
LivaNova, listed on...